Have Aeon Biopharma insiders bought shares recently?

Yes. Insiders of Aeon Biopharma (AEON) filed 1 open-market purchase in the last 90 days; the latest was filed on Aug 21, 2026.

How often do Aeon Biopharma insiders buy and sell shares?

Since 2023, Aeon Biopharma insiders reported 4 open-market purchases and 1 sale on Forms 4 and 5, with purchases in 2 different years, most recently 2026.

Who is selling Aeon Biopharma stock?

No open-market sale by an insider of Aeon Biopharma (AEON) was filed with the SEC in the last 90 days.

Do members of Congress trade AEON?

No trade in Aeon Biopharma (AEON) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Aeon Biopharma (AEON) insider trading and stock trades

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at AEON buy and sell in the last 90 days?Which members of Congress and which funds traded AEON recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

AEON price and disclosed activity

−83.7% (−$0.787) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Show the 1 trade in this range as a list

LYNCH TIMOTHY P, 10% owner · Insider purchase, about $243Ktraded Aug 19, 2026, filed Aug 21, 2026

Insider open-market trades, filed in the last 90 days1 buy · 0 sales~$243K boughtInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, last 12 monthsNoneNo followed fund reported a changeFund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Pharmaceutical Preparations company based in Aliso Viejo, Ca.

Last 12 months

−83.7%

S&P 500 +12.3% over the same dates

Market value

$7.63M

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.

Short interest: 2.66M shares sold short (5.3% of shares outstanding), −18.1% vs the previous count, 6.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

Last 30 days

Written by software from the filings listed below · Nov 14, 2026

Funds and stakes. Aeon Biopharma on OQRO: Nantahala Capital Management, LLC now owns 10.0% of AEON as a passive investor (filed Nov 13, 2026). Daewoong Co., Ltd. disclosed a 30.6% stake in AEON (filed Nov 10, 2026).

3 more points, with the facts they come from, are in OQRO Pro.

Latest results: quarter ending Jun 30, 2026

Revenue

—

Free cash flow, last 12 months

—

Cash from operations minus capital spending

Net debt

—

Debt —, cash $3.43M, at Jun 30, 2026

Net income, last 12 months

−$54.6M

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 12, 2026.

Insider buying and selling since 2023

Insiders of Aeon Biopharma reported 4 open-market purchases and 1 sale since 2023; purchases in 2 different years, most recently 2026.

Year	Bought	Sold
2026	$243K1×1 trade	—
2025	$85K3×3 trades	—
2023	—	$73.8M1×1 trade

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.

Red flags in its filings

Apr 3
Notice of delisting or failure to meet listing rules
8-K on sec.gov

From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.

Holders above 5%

Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.

Latest

See everything

Fund moves

13G stake

10.0%Stake · was 10.0%

Filed 2d ago

A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.

More Official record

Fund moves

Want the short version?

Aeon Biopharma

How this filing works

Questions about Aeon Biopharma insider trading

Insiders who traded Aeon Biopharma

Other Pharmaceutical Preparations companies

AEON price and disclosed activity

Last 30 days

Latest results: quarter ending Jun 30, 2026

Insider buying and selling since 2023

Red flags in its filings

Holders above 5%

Latest

10.0%Stake · was 10.0%

30.6%Stake

~$243K1.15M sh @ $0.2117

~$60Kacross 2 transactionsin 2 filings

Holders above 5%

Last 30 days

Insider buying and selling since 2023

Red flags in its filings